JP2023517535A5 - - Google Patents

Info

Publication number
JP2023517535A5
JP2023517535A5 JP2022552937A JP2022552937A JP2023517535A5 JP 2023517535 A5 JP2023517535 A5 JP 2023517535A5 JP 2022552937 A JP2022552937 A JP 2022552937A JP 2022552937 A JP2022552937 A JP 2022552937A JP 2023517535 A5 JP2023517535 A5 JP 2023517535A5
Authority
JP
Japan
Prior art keywords
day
administered
stereoisomer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/055147 external-priority patent/WO2021175831A2/en
Publication of JP2023517535A publication Critical patent/JP2023517535A/ja
Publication of JP2023517535A5 publication Critical patent/JP2023517535A5/ja
Pending legal-status Critical Current

Links

JP2022552937A 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物 Pending JP2023517535A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382152.5 2020-03-02
EP20382192 2020-03-13
EP20382192.1 2020-03-13
EP20382266.3 2020-04-02
EP20382266 2020-04-02
EP20382339.8 2020-04-27
EP20382339 2020-04-27
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382816.5 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25
PCT/EP2021/055147 WO2021175831A2 (en) 2020-03-02 2021-03-02 Compounds for use in viral infections

Publications (2)

Publication Number Publication Date
JP2023517535A JP2023517535A (ja) 2023-04-26
JP2023517535A5 true JP2023517535A5 (cg-RX-API-DMAC7.html) 2024-03-12

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552946A Pending JP2023517536A (ja) 2020-03-02 2021-03-02 炎症状態に使用するための化合物
JP2022552937A Pending JP2023517535A (ja) 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022552946A Pending JP2023517536A (ja) 2020-03-02 2021-03-02 炎症状態に使用するための化合物

Country Status (17)

Country Link
US (2) US12630589B2 (cg-RX-API-DMAC7.html)
EP (2) EP4114433A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023517536A (cg-RX-API-DMAC7.html)
KR (2) KR20220151643A (cg-RX-API-DMAC7.html)
CN (2) CN115666616A (cg-RX-API-DMAC7.html)
AU (2) AU2021232535A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016604A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169540A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002396A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014031A2 (cg-RX-API-DMAC7.html)
IL (2) IL296069A (cg-RX-API-DMAC7.html)
MX (2) MX2022010921A (cg-RX-API-DMAC7.html)
PE (2) PE20230412A1 (cg-RX-API-DMAC7.html)
PY (2) PY2117301A (cg-RX-API-DMAC7.html)
TW (2) TW202144381A (cg-RX-API-DMAC7.html)
UY (2) UY39110A (cg-RX-API-DMAC7.html)
WO (2) WO2021175831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114436A1 (en) * 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) * 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909668A (pt) * 1998-04-14 2000-12-19 Jomaa Hassan Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115666616A (zh) * 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物

Similar Documents

Publication Publication Date Title
KR102711661B1 (ko) 구역과 구토를 치료하기 위한 아미설프리드 및 추가의 구토 방지제의 병용
CN114641293A (zh) 一种fgfr抑制剂的用途
JP2023002544A5 (cg-RX-API-DMAC7.html)
JP2016530280A5 (cg-RX-API-DMAC7.html)
JP2020143143A (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2019514974A5 (cg-RX-API-DMAC7.html)
JP2020516646A5 (cg-RX-API-DMAC7.html)
JP2013518124A5 (cg-RX-API-DMAC7.html)
CN111867582A (zh) 衣壳组装调节剂给药方案
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
KR20220151643A (ko) 바이러스 감염에 사용하기 위한 화합물
JP2022544485A5 (cg-RX-API-DMAC7.html)
JP2023517536A5 (cg-RX-API-DMAC7.html)
JP2023520004A5 (cg-RX-API-DMAC7.html)
JP2024010018A (ja) うつ病を治療するための組成物および方法
WO2021231941A1 (en) Tlr7/8 antagonists for the treatment of coronavirus infections
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP7186735B2 (ja) 注腸剤
JP2023517194A (ja) コロナウイルス感染の処置における組合せに使用するためのpld
JP2021004249A5 (cg-RX-API-DMAC7.html)
JP2011506607A5 (cg-RX-API-DMAC7.html)
JP2023517295A5 (cg-RX-API-DMAC7.html)
EP3937928A1 (en) Capsid assembly modulator solid formulation